Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis
- 1 February 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 17 (2) , 195-201
Abstract
Rationale: In cystic fibrosis, information on the efficacy of azithromycin past 12 months of treatment is still scarce. Objectives: The study sought to quantify the changes in lung function and the number of intravenous antibiotic courses (IVACs) after initiation of azithromycin in patients included in the French Cystic Fibrosis Registry. Methods: The study followed 1,065 children and 990 adults from 2 years before to 5 years after long-term azithromycin treatment initiated between 2001 and 2011. Mixed change-point models were used to quantify the changes in the forced expiratory volume (FEV) in 1 second and the yearly number of IVACs. Results: In the year of treatment initiation, the mean FEV was significantly higher than expected (+1.6%, P = 0.007 in children; +1.3%, P = 0.02 in adults). The decline of the FEV over time was less marked after than before treatment initiation (slope difference = +0.7% per year [P = 0.03] in children and +0.6% per year [P = 0.06] in adults). The mean increase in the yearly number of IVACs was lower after than before treatment initiation. The rate ratio quantifying the effect on the mean increase was 0.93 (95% confidence interval = [0.88–0.99]; P = 0.02) in children and 0.95 (95% confidence interval = [0.90–1.01]; P = 0.08) in adults. Conclusions: In children, long-term azithromycin treatment was associated with immediate and sustained beneficial changes in lung function and sustained beneficial changes in the frequency of pulmonary exacerbations. In adults, it was associated with immediate beneficial changes in lung function.Keywords
This publication has 25 references indexed in Scilit:
- An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellaneaJournal of Cystic Fibrosis, 2011
- The Role of Azithromycin in Patients with Cystic FibrosisPaediatric Respiratory Reviews, 2010
- A random change point model for assessing variability in repeated measures of cognitive functionStatistics in Medicine, 2008
- Cystic fibrosisBMJ, 2007
- Dailyversusweekly azithromycin in cystic fibrosis patientsEuropean Respiratory Journal, 2007
- Maintenance Azithromycin Treatment in Pediatric Patients With Cystic FibrosisThe Pediatric Infectious Disease Journal, 2007
- Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trialThorax, 2006
- Random changepoint modelling of HIV immunologic responsesStatistics in Medicine, 2006
- Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trialThorax, 2002
- Anti‐inflammatory effects of macrolides in lung disease*Pediatric Pulmonology, 2001